References
- Moreno-Aspitia A, Perez EA. Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc 2009;84:533–545
- Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 2004;9:3–8
- Yared JA, Tkaczuk KH. Update on taxane development: new analogs and new formulations. Drug Des Devel Ther 2012;6:371–384
- Carvalho C, Santos RX, Cardoso S, et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 2009;16:3267–3285
- Rivankar S. An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther 2014;10:853–858
- Cella D, Peterman A, Hudgens S, et al. Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane). Cancer 2003;98:822–831
- Lau CP, Hui P, Chan TC. Docetaxel-induced nail toxicity: a case of severe onycholysis and topic review. Chin Med J (Engl) 2011;124:2559–2560
- Almagro M, Pozo JD, Garcia J, et al. Nail alterations secondary to pactitaxel [corrected] therapy. Eur J Dermatol 2000;10:146–147
- Roh MR, Cho JY, Lew W. Docetaxel-induced onycholysis: the role of subungual hemorrhage and suppuration. Yonsei Med J 2007;48:124–126
- Lüftner D, Flath B, Akrivakis C, et al. Dose-intensified weekly paclitaxel induces multiple nail disorders. Ann Oncol 1998;9:1139–1140
- Garshick MK, Myskowski P, Scher R. Paclitaxel-associated melanonychia. Cutis 2015;95:E12–E14
- Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol 2008;58:545–570
- Can G, Aydiner A, Cavdar I. Taxane-induced nail changes: predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity. Eur J Oncol Nurs 2012;16:270–275
- Capriotti K, Capriotti JA, Lessin S, et al. The risk of nail changes with taxane chemotherapy: a systematic review of the literature andmeta-analysis. Br J Dermatol 2015;173:842–845
- Baker J, Ajani J, Scotté F, et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009;13:49–59
- Robert C, Sibaud V, Mateus C, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol 2015;16:e181–e189
- Piraccini BM, Alessandrini A. Drug-related nail disease. Clin Dermatol 2013;31:618–626
- Spazzapan S, Crivellari D, Lombardi D, et al. Nail toxicity related to weekly taxanes: an important issue requiring a change in commontoxicity criteria grading? J Clin Oncol 2002;20:4404–4405.
- Minisini AM, Tosti A, Sobrero AF, et al. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol 2003;14:333–337
- Alexandrescu DT, Vaillant J, Wiernik PH. Trastuzumab/docetaxel-induced nail dystrophy. Int J Dermatol 2006;45:1334–1336
- Mourad YA, Matta-Muallem M, Shamseddine A. Nail toxicity related to taxanes. Dermatol Online J 2003;9:15
- Gilbar P, Hain A, Peereboom VM. Nail toxicity induced by cancer chemotherapy. J Oncol Pharm Pract 2009;15:143–155
- Abbasi NR, Wang N. Doxorubicin-induced hyperpigmentation. Dermatol Online J 2008;14:18
- Manigand G, Faux N, Dumas D, et al. [Nail pigmentation during therapy with cyclophosphamide and doxorubicin]. Sem Hop 1983;59:1840–1841
- Giacobetti R, Esterly NB, Morgan ER. Nail hyperpigmentation secondary to therapy with doxorubicin. Am J Dis Child 1981;135:3417–3418
- Lopes M, Jordão C, Grynszpan R, et al. Chromonychia secondary to chemotherapy. Case Rep Dermatol 2013;5:163–167
- Piraccini BM, Dika E, Fanti PA. Tips for diagnosis and treatment of nail pigmentation with practical algorithm. Dermatol Clin 2015;33:185–195
- Di Chiacchio ND, Farias DC, Piraccini BM, et al. Consensus on melanonychia nail plate dermoscopy. An Bras Dermatol 2013;88:309–313
- Ronger S, Touzet S, Ligeron C, et al. Dermoscopic examination of nail pigmentation. Arch Dermatol 2002;138:1327–1333
- Wasner G, Hilpert F, Baron R, Pfisterer J. Clinical picture: nail changes secondary to docetaxel. Lancet 2001;357:910